Physician profile
Robert Otto Bauer
NPI 1508240250
$2,603.85
in general payments reported to CMS, 2019-2025
18 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $675 · 2021: $127 · 2022: $53.96 · 2023: $260 · 2024: $454 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $533.06 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $495.53 | 2019-2025 | Nuedexta, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $376.30 | 2019-2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $301.76 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $241.27 | 2019-2020 | |
| Allergan, INC. | $125.29 | 2020 | |
| Alkermes, INC. | $119.04 | 2019-2025 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $115.68 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $59.96 | 2020-2024 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $56.78 | 2023 | Auvelity |
| Sage Therapeutics, LLC | $32.89 | 2024-2025 | Zurzuvae |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.11 | 2022-2023 | Caplyta |
| Ironshore Pharmaceuticals INC. | $24.78 | 2019-2020 | |
| Tris Pharma INC | $20.00 | 2023 | Dyanavel Xr |
| Corium, LLC | $17.89 | 2023 | Azstarys |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $17.45 | 2020 | |
| Novo Nordisk INC | $17.03 | 2020 | |
| Indivior INC. | $17.03 | 2025 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.